Ionis Announces Submission of Marketing Authorization Application for Inotersen to the EMA Post author:Sam Post published:November 2, 2017 Post category:BioPharma The MAA will be reviewed under the EMA’s Accelerated Assessment program. Source: BioSpace You Might Also Like Keryx To Host Conference Call Of First Quarter 2017 Financial Results On Thursday, May 4, 2017 April 17, 2017 Telix Pharma, Release: Companies Conclude Therapeutic Product Development Agreement For Prostate Cancer January 18, 2017 Immunomedics Announces Fiscal 2017 Results And Strategic Developments; Reiterates Guidance On BLA Submission Timeline August 16, 2017
Keryx To Host Conference Call Of First Quarter 2017 Financial Results On Thursday, May 4, 2017 April 17, 2017
Telix Pharma, Release: Companies Conclude Therapeutic Product Development Agreement For Prostate Cancer January 18, 2017
Immunomedics Announces Fiscal 2017 Results And Strategic Developments; Reiterates Guidance On BLA Submission Timeline August 16, 2017
